Pharmacokinetic studies of 68Ga-labeled bombesin ( 68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: Preliminary results

Clinical Nuclear Medicine

Volumn 36, Issue 2, 2011, Pages 101-108

  Dimitrakopoulou Strauss, Antonia ^a   Seiz, Marcel ^b   Tuettenberg, Jochen ^b   Schmieder, Kirsten ^b   Eisenhut, Michael ^a   Haberkorn, Uwe ^a,c   Strauss, Ludwig G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

68Ga Bombesin; FDG; gliomas; kinetic modeling; PET

Indexed keywords

BOMBESIN DERIVATIVE; BOMBESIN GALLIUM 68; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BOMBESIN; DIAGNOSTIC AGENT; GALLIUM;

ARTICLE; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; COMPARATIVE STUDY; GLIOMA; HUMAN; POSITRON EMISSION TOMOGRAPHY; SCINTIGRAPHY; DISCRIMINANT ANALYSIS; METABOLISM; PATHOLOGY; RECURRENT DISEASE; SCINTISCANNING;

BOMBESIN; DISCRIMINANT ANALYSIS; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; GLIOMA; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE;

EID: 79551589409     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318203bb24     Document Type: Article

References (35)

1. Brat DJ, Prayson RA, Ryken TC, et al. Diagnosis of malignant glioma: role of neuropathology. JNeurooncol. 2008;89:287-311.
2. Pierallini A, Bonamini M, Bozzao A, et al. Supratentorial diffuse astrocytic tumors: proposal of an MRI classification. Eur Radiol. 1997;7:395-399.
3. Earnest FT, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: his-topathologic correlation of MR and CT contrast enhancement with stereotac-tic biopsy. Radiology. 1988;166:823-827.
4. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-648.
5. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007; 48:1468-1481.
6. Sharif TR, Luo W, Sharif M. Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol Cell Endocrinol. 1997;130:119-130.
7. Wada E, Way J, Shapira H, et al. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron. 1991;6:421-430.
8. Wang LH, Battey JF, Wada E, et al. Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Ca2 + and phosphoinositides. Biochem J. 1992;286:641-648.
9. Schuhmacher J, Zhang H, Doll J, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a (68)Ga-labeled Bombesin (6-14) analog. J Nucl Med. 2005;46:691-699.
10. Toorongian SA, Mulholland GK, Jewett DM, et al. Routine production of 2-deoxy-2 (18F)fluoro-D-glucose by direct nucleophilic exchange on a qua-ternary 4-aminopyridinium resin. Nucl Med Biol. 1990;3:273-279.
11. Burger C, Buck A. Requirements and implementations of a flexible kinetic modelingtool. J Nucl Med. 1997;38:1818-1823.
12. Mikolajczyk K, Szabatin M, Rudnicki P, et al. A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform. 1998;23:207-214.
13. Miyazawa H, Osmont A, Petit-Taboue MC, et al. Determination of 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods. 1993;50:263-272.
14. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991;32:1432-1438.
15. Dimitrakopoulou-Strauss A, Strauss LG, Mikolajczyk K, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med. 2003;2:306-313.
16. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, et al. Characterization of 68Ga-DOTA-D-PHE1-TYR3-octreotide kinetics in patients with meningi-omas. J Nucl Med. 2005;46:763-769.
17. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, et al. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using 68Ga-DOTATOC PET and comparison to 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2006;33:823-830.
18. Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharma-cokinetics of (68)Ga-DOTATOC in patients with metastatic neuroendocrine tumors scheduled for (90)Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2005;33:460-466.
19. Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.
20. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, et al. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tu-mors: comparison to 18F-FDG. J Nucl Med. 2007;48:1245-1250.
21. Jensen RT, Battey JF, Spindel ER, et al. International union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, phar-macology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60:1-42.
22. Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, et al. 68Ga-Bombesin (68Ga-BZH3) and 18F-FDG studies in patients (pts.) with suspected recur-rent low-grade gliomas (LGG). J Nucl Med. 2008;49(suppl 1):79P.
23. Seiz M, Dimitrakopoulou-Strauss A, Schubert GA, et al. Differentiation between malignant transformation and tumor recurrence by (68)Ga-bombesin and (18)F-FDG-PET in patients with low grade gliomas. Hell J Nucl Med. 2008;11:149-152.
24. Di Chiro, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by 18F-fluordeoxyglucose and positron emission tomog-raphy. Neurology. 1982;32:1323-1329.
25. Patronas NJ, Brooks RA, DeLaPaz RL, et al. Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. Am J Neuroradiol. 1983;4:533-555.
26. Borbely K, Nyary I, Toth M, et al. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci. 2006;246:85-94.
27. Kaschten B, Stevemaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-me-thionine. J Nucl Med. 1998;39:778-785.
28. Pöpperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47:393-403.
29. Yamamoto Y, Nishiyama Y, Kimura N, et al. 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol. 2008;10:281-287.
30. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-429.
31. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med. 2004;45:1528-1535.
32. Charnley N, Airley R, Du Plessis D, et al. No relationship between 18F-fluorodeoxyglucose and expression ofGlut-1 and-3 and hexokinase I and II in high-grade glioma. Oncol Rep. 2008;20:537-542.
33. Pan L, Mikolajczyk K, Strauss L, et al. Machine learning based parameter imaging and kinetic modeling of PET data. J Nucl Med. 2007;48(suppl2):158P.
34. Takano S, Kamiyana H, Tsuboi K, et al. Angiogenesis and antiagiogenic therapy for malignant gliomas. Brain Tumor Pathol. 2004;21:69-73.
35. Weckesser M, Langen KJ, Rickert CH, et al. O-(2[18F]fluorethyl)-L- tyrosine PET in the clinical evaluation of primary brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:422-429.